Livforsakringsbolaget Skandia Omsesidigt reduced its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 5.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,696 shares of the medical research company’s stock after selling 3,600 shares during the quarter. Amgen comprises about 1.0% of Livforsakringsbolaget Skandia Omsesidigt’s portfolio, making the stock its 18th biggest position. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Amgen were worth $10,207,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nippon Life Global Investors Americas Inc. boosted its stake in Amgen by 247.6% in the second quarter. Nippon Life Global Investors Americas Inc. now owns 51,000 shares of the medical research company’s stock valued at $8,785,000 after acquiring an additional 36,330 shares during the last quarter. Signature Financial Management Inc. bought a new position in Amgen in the second quarter valued at approximately $231,000. Advisors Asset Management Inc. boosted its stake in Amgen by 8.6% in the second quarter. Advisors Asset Management Inc. now owns 70,307 shares of the medical research company’s stock valued at $12,109,000 after acquiring an additional 5,550 shares during the last quarter. United Asset Strategies Inc. boosted its stake in Amgen by 5.9% in the second quarter. United Asset Strategies Inc. now owns 22,495 shares of the medical research company’s stock valued at $3,874,000 after acquiring an additional 1,250 shares during the last quarter. Finally, Blue Fin Capital Inc. boosted its stake in Amgen by 1.0% in the second quarter. Blue Fin Capital Inc. now owns 6,306 shares of the medical research company’s stock valued at $1,086,000 after acquiring an additional 65 shares during the last quarter. 78.03% of the stock is currently owned by institutional investors and hedge funds.
In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 4,575 shares of company stock worth $818,361. 0.19% of the stock is currently owned by company insiders.
Shares of Amgen, Inc. (AMGN) opened at $182.45 on Friday. Amgen, Inc. has a twelve month low of $152.16 and a twelve month high of $201.23. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. The company has a market cap of $131,452.16, a price-to-earnings ratio of 70.99, a P/E/G ratio of 2.18 and a beta of 1.42.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. During the same quarter in the previous year, the business earned $2.89 earnings per share. The company’s revenue was down 2.7% on a year-over-year basis. analysts predict that Amgen, Inc. will post 13.21 EPS for the current year.
Amgen announced that its Board of Directors has approved a share repurchase program on Thursday, February 1st that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.89%. This is a positive change from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date is Wednesday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 205.45%.
AMGN has been the topic of a number of recent research reports. BMO Capital Markets reaffirmed a “market perform” rating and issued a $198.00 price objective on shares of Amgen in a research note on Thursday, October 26th. BidaskClub raised shares of Amgen from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 2nd. Goldman Sachs Group cut shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. Sixteen analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $191.84.
WARNING: “Amgen, Inc. (AMGN) Shares Sold by Livforsakringsbolaget Skandia Omsesidigt” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/23/amgen-inc-amgn-shares-sold-by-livforsakringsbolaget-skandia-omsesidigt.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.